Results for relative potency unit translation from English to Danish

relative potency
relativ styrke

rep relative potency
rep relativ styrke

relative potency (r.p.)
relativ potens (rp)

relative potency (r. p.) 9.50 -12.25
relativ potens (r. p.) 9, 50 ­ 12, 25

2 relative potency units defined against a reference vaccine.
2 relativ potens sammenlignet med en referencevaccine.

relative potency (elisa test) by comparison with a reference vaccine
relativ potency (elisa test) ved sammenligning med referencevaccine

*relative potency by in vitro method, compared to a reference vaccine that was shown efficacious in horses.
* relativ styrke in vitro sammenlignet med en referencevaccine, der var påvist effektiv til heste.

for other strong cyp3a4 inhibitors, such as clarithromycin, indinavir and saquinavir, a less pronounced effect can be expected, based on their relative potency.
for andre potente cyp3a4-hæmmere, for eksempel clarithromycin, indinavir og saquinavir, kan der forventes en mindre udtalt effekt, baseret på deres relative styrke.

the relative potencies of iaa and aa were compared in female guineapigs after a 6-day depletion diet.
de relative styrker af ias og as blev sammenlignet i hunmarsvin efter en 6­dages depletionsdiæt.

for each sample of tuberculin under test, an estimate of relative potency against the appropriate standard and its fiducial limits shall be made by statistical methods, using the diameters of the reactions and the logarithms of the doses as metameters.
for hver prøve af det tuberkulin, der skal bestemmes, beregnes den relative styrke og referensbegrænsninger ved hjælp af statistiske metoder, idet reaktionernes diameter og dosernes logaritmer anvendes som metametre.

porcine circovirus type 2 orf2 protein: minimum rp* 1.0 maximum rp* 3.75 * relative potency (elisa test) by comparison with a reference vaccine
porcint circovirus type 2 orf2- protein: minimum rp * 1, 0 maksimum rp * 3, 75 * relativ potency (elisa test) ved sammenligning med referencevaccine

porcine circovirus type 2 orf2 protein: minimum rp* 1.0, maximum rp* 3.75 * relative potency (elisa test) by comparison with a reference vaccine.
porcint circovirus type 2 orf2-protein: min.rp * 1, 0, max.rp * 3, 75 * relativ potency (elisa test) ved sammenligning med referencevaccine.

adjuvant:porcine circovirus type 2 orf2 protein: minimum rp* 1.0 maximum rp* 3.75 * relative potency (elisa test) by comparison with a reference vaccine
porcint circovirus type 2 orf2-protein: minimum rp * 1, 0 maksimum rp * 3, 75 * relativ potency (elisa test) ved sammenligning med referencevaccineadjuvans:

based on exposure, relative potency, and pharmacokinetic properties, both hydroxy- and desmethyl-dabrafenib are likely to contribute to the clinical activity of dabrafenib. while the activity of carboxy-dabrafenib is not likely to be significant.
baseret på eksponering, relativ potens og farmakokinetiske egenskaber synes både hydroxy- og desmethyldabrafenib at bidrage til den kliniske effekt af dabrafenib, mens aktiviteten af carboxydabrafenib ikke synes at være signifikant.

it aims at correcting factors like the loss of pcdd/pcdfs and dioxin-like compounds during the extraction and clean-up steps, co-extracted compounds increasing or decreasing the response (agonistic and antagonistic effects), the quality of the curve fit, or differences between the toxic equivalency factor (tef) and the relative potency (rep) values.
formålet er at korrigere for faktorer såsom tabet af pcdd'er/pcdf'er og dioxinlignende forbindelser i ekstraktions– og oprensningsfasen, medekstraherede forbindelser, som forstærker eller svækker responset (henholdsvis agonistisk og antagonistisk virkning), kvaliteten af kurvetilpasningen eller forskelle mellem værdierne for henholdsvis toksicitetsækvivalensfaktoren (tef) og den relative styrke (rep).